Conditions of MTC in clients handled with liraglutide, another GLP-one receptor agonist, have already been claimed in the postmarketing period of time; the data in these reports are inadequate to establish or exclude a causal relationship involving MTC and GLP-one receptor agonist use in humans.The observed incidence of anti-drug antibodies is very